Vaginal Candida albicans: High Frequency of in Vitro Fluconazole Resistance in a Select Population-A Brief Note

Pranjal Agrawal; Golsa Yazdy; Khalil G Ghanem; Victoria L Handa; Christina M Schumacher; Jack D Sobel; Sean X Zhang; Susan Tuddenham

doi:10.1097/OLQ.0000000000001730

Vaginal Candida albicans: High Frequency of in Vitro Fluconazole Resistance in a Select Population-A Brief Note

Sex Transm Dis. 2023 Feb 1;50(2):121-123. doi: 10.1097/OLQ.0000000000001730. Epub 2022 Nov 1.

Authors

Pranjal Agrawal¹, Golsa Yazdy², Khalil G Ghanem³, Victoria L Handa², Christina M Schumacher⁴, Jack D Sobel⁵, Sean X Zhang⁶, Susan Tuddenham³

Affiliations

¹ From the Johns Hopkins University School of Medicine.
² Department of Gynecology and Obstetrics.
³ Division of Infectious Diseases, Department of Medicine.
⁴ Center for Child and Community Health Research, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.
⁵ Division of Infectious Disease, Wayne State University, Detroit, MI.
⁶ Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.

PMID: 36630418
DOI: 10.1097/OLQ.0000000000001730

No abstract available

Plain language summary

Among clinician-ordered vaginal cultures positive for Candida albicans , 30% exhibited fluconazole resistance. Resistance did not reliably predict future susceptibility. Prospective studies to verify associations with demographic and clinical factors as well as to correlate in vitro resistance with treatment response and longitudinal resistance patterns are needed.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antifungal Agents / pharmacology
Antifungal Agents / therapeutic use
Candida albicans
Candidiasis, Vulvovaginal* / drug therapy
Female
Fluconazole* / pharmacology
Humans
Microbial Sensitivity Tests
Vagina

Substances

Fluconazole
Antifungal Agents

Grants and funding

K23 AI125715/AI/NIAID NIH HHS/United States